This is an old revision of this page, as edited by Pashihiko (talk | contribs) at 02:48, 4 January 2011. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 02:48, 4 January 2011 by Pashihiko (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | |
| Names | |
|---|---|
| IUPAC name 4-Amino-5-fluoro-1-pyrimidin-2-one | |
| Other names Reverset | |
| Identifiers | |
| CAS Number | |
| 3D model (JSmol) | |
| KEGG | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
SMILES
| |
| Properties | |
| Chemical formula | C9H10FN3O3 |
| Molar mass | 227.19 g/mol |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references | |
Dexelvucitabine is a failed experimental agent for the treatment of HIV. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.
On April 3, 2006, Pharmasset and Incyte Corporation, the pharmaceutical companies developing dexelvucitabine announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia in a phase II trial.
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |